Matches in Wikidata for { <http://www.wikidata.org/entity/Q104060029> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- Q104060029 description "2020 ވަނަ އަހަރުގެ ޑިސެމްބަރުމަހުގެ 3ވަނަ ދުވަހު ޝާއިރުކުރެވުނު ސައިންޓިފިކް ލިޔުމެއް" @default.
- Q104060029 description "article scientifique publié en 2020" @default.
- Q104060029 description "artículu científicu espublizáu n'avientu de 2020" @default.
- Q104060029 description "scientific article published on 03 December 2020" @default.
- Q104060029 description "wetenschappelijk artikel" @default.
- Q104060029 description "наукова стаття, опублікована 3 грудня 2020" @default.
- Q104060029 name "Efficacy and safety of chronomodulated Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: results from the international EORTC 05011 trial" @default.
- Q104060029 name "Efficacy and safety of chronomodulated Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: results from the international EORTC 05011 trial" @default.
- Q104060029 name "Efficacy and safety of chronomodulated Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: results from the international EORTC 05011 trial" @default.
- Q104060029 type Item @default.
- Q104060029 label "Efficacy and safety of chronomodulated Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: results from the international EORTC 05011 trial" @default.
- Q104060029 label "Efficacy and safety of chronomodulated Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: results from the international EORTC 05011 trial" @default.
- Q104060029 label "Efficacy and safety of chronomodulated Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: results from the international EORTC 05011 trial" @default.
- Q104060029 prefLabel "Efficacy and safety of chronomodulated Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: results from the international EORTC 05011 trial" @default.
- Q104060029 prefLabel "Efficacy and safety of chronomodulated Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: results from the international EORTC 05011 trial" @default.
- Q104060029 prefLabel "Efficacy and safety of chronomodulated Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: results from the international EORTC 05011 trial" @default.
- Q104060029 P1433 Q104060029-9B817468-71BA-4018-A3FF-1F2B24FAA706 @default.
- Q104060029 P1476 Q104060029-6766C643-6AFD-47F0-8B5C-A117F9619CDD @default.
- Q104060029 P2093 Q104060029-0571297B-A021-44BA-8A7C-D28C8DA39DFC @default.
- Q104060029 P2093 Q104060029-3926409C-94D9-4125-BEDE-834F7A161475 @default.
- Q104060029 P2093 Q104060029-4E111AA0-12F9-4DFD-828A-0A7B3B148061 @default.
- Q104060029 P2093 Q104060029-671CAFC4-6563-4F4C-93C3-9335A0FA9F9C @default.
- Q104060029 P2093 Q104060029-7863A209-C563-44B5-9246-3E6F546551DF @default.
- Q104060029 P2093 Q104060029-86FC2AB2-2DDA-44FF-B5E8-E6B074CA61C0 @default.
- Q104060029 P2093 Q104060029-A39B8B71-8346-4568-8049-E70A3063E85A @default.
- Q104060029 P2093 Q104060029-A83F0BD8-2C44-4480-81DC-91628F03FC4C @default.
- Q104060029 P2093 Q104060029-F3464F8A-A237-414E-99EF-3C5061B259B2 @default.
- Q104060029 P2093 Q104060029-F95F7E81-A8A5-444A-9949-ABAF7DC01DD3 @default.
- Q104060029 P31 Q104060029-58E4245F-11F0-4596-8706-E4A784F00B3E @default.
- Q104060029 P356 Q104060029-C0A30A18-9C19-44C6-9E7D-250CC7F13587 @default.
- Q104060029 P50 Q104060029-CBA15C5A-8502-4B79-A17D-7F818B010E0F @default.
- Q104060029 P577 Q104060029-C7615CC4-CE94-4D0E-84F7-E369C23CA0C6 @default.
- Q104060029 P698 Q104060029-C78C9464-3C21-4422-973C-16024CD886DD @default.
- Q104060029 P921 Q104060029-14BE88EA-AF69-40AF-8E70-22A03BB57016 @default.
- Q104060029 P921 Q104060029-282854B6-A7CC-4404-A661-094C741DFAFC @default.
- Q104060029 P921 Q104060029-F5BF85D1-476D-48C6-9431-46951327869F @default.
- Q104060029 P921 Q104060029-FFADC73C-B000-4275-9C24-E4080F2AD54D @default.
- Q104060029 P932 Q104060029-7454BFA8-35CE-44E5-ADFB-46B4B79EFB16 @default.
- Q104060029 P356 IJC.33422 @default.
- Q104060029 P698 33270911 @default.
- Q104060029 P1433 Q332492 @default.
- Q104060029 P1476 "Efficacy and safety of chronomodulated Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: results from the international EORTC 05011 trial" @default.
- Q104060029 P2093 "Abdoulaye Karaboué" @default.
- Q104060029 P2093 "Angela Torsello" @default.
- Q104060029 P2093 "Ayhan Ulusakarya" @default.
- Q104060029 P2093 "Carlo Garufi" @default.
- Q104060029 P2093 "Christian Focan" @default.
- Q104060029 P2093 "Francis A Lévi" @default.
- Q104060029 P2093 "Mohamed Bouchahda" @default.
- Q104060029 P2093 "Philippe Chollet" @default.
- Q104060029 P2093 "René Adam" @default.
- Q104060029 P2093 "Sylvie Giacchetti" @default.
- Q104060029 P31 Q13442814 @default.
- Q104060029 P356 "10.1002/IJC.33422" @default.
- Q104060029 P50 Q87770979 @default.
- Q104060029 P577 "2020-12-03T00:00:00Z" @default.
- Q104060029 P698 "33270911" @default.
- Q104060029 P921 Q108566365 @default.
- Q104060029 P921 Q238512 @default.
- Q104060029 P921 Q412197 @default.
- Q104060029 P921 Q422327 @default.
- Q104060029 P932 "8048520" @default.